Skip to main content
EJNMMI Radiopharmacy and Chemistry

Table 2 Yield, purity, and molar activity of [11C]7m6BP after purification and formulation

From: Improved synthesis of 6-bromo-7-[11C]methylpurine for clinical use

View full size image

Solvent

Activity (GBq)a

Yield (GBq)b

Time (min)c

Yield (%)d

RCP (%)e

Am (GBq/µmol)f

Ratiog

ACT

28

1.1

31

11

99

130

0.41

ACT

28

0.95

30

9.2

99

79

0.40

ACT

29

0.65

32

6.6

99

170

0.40

DMSO

29

0.50

29

4.6

97

100

0.42

DMSO

29

0.82

29

7.7

92

140

0.52

DMSO

29

0.87

31

8.7

87

130

0.62

THF

28

2.3

32

24

95

170

1.3

THF

28

2.6

32

28

95

140

1.5

THF

29

2.6

32

26

96

180

1.2

2-MeTHF

29

2.9

31

29

96

200

2.0

2-MeTHF

33

3.9

31

35

95

150

2.2

2-MeTHF

28

2.8

31

29

97

98

1.7

1,4-DO

30

1.1

31

11

98

140

1.3

1,4-DO

30

1.2

30

11

96

190

1.3

1,4-DO

29

1.1

31

11

95

160

1.3

AcOEt

34

2.7

30

22

98

160

1.2

AcOEt

31

3.3

32

31

98

140

1.2

AcOEt

29

3.0

31

30

97

110

1.3

  1. Automated synthesis of [11C]7m6BP using [11C]CH3OTf (n = 3)
  2. aInitial activity of [11C]CO2 at EOB
  3. bIsolated yield at end of synthesis (EOS)
  4. cTotal synthesis time from EOB to EOS
  5. dIsolated yield (decay corrected to the EOB)
  6. eRadiochemical purity at 60 min after synthesis
  7. fMolar activity at EOS
  8. gRatio of the peak area for [11C]7m6BP to [11C]9m6BP calculated from each HPLC chromatogram
Back to article page